Showing 2471-2480 of 5771 results for "".
- Wize Pharma Announces Presentation of New Data on LO2A in the Treatment of Dry Eye Syndrome in Patients with Sjögren’s Syndromehttps://modernod.com/news/wize-pharma-announces-presentation-of-new-data-on-lo2a-in-the-treatment-of-dry-eye-syndrome-in-patients-with-sjogrens-syndrome/2480143/Wize Pharma announced recently reported new data on a formula known as LO2A, a product that Wize has in-licensed certain rights to purchase, market, sell and distribute. The poster presentation presented at the Association for Research in Vision and Ophthalmology (ARVO) 2018 Annual Meeting
- Ocular Therapeutix Announces Treatment of First Patient in Phase 1 Clinical Trial of OTX-TIC for the Treatment of Glaucomahttps://modernod.com/news/ocular-therapeutix-announces-treatment-of-first-patient-in-phase-1-clinical-trial-of-otx-tic-for-the-treatment-of-glaucoma-and-ocular-hypertension/2480177/Ocular Therapeutix announced the treatment of the first patient in a phase 1, open-label, proof-of-concept clinical trial being conducted in the United States for OTX-TIC, a bioresorbable travoprost implant delivered via an intracameral injection for the reduction of IOP in patients with glaucoma
- Iridex Announces Increase in Micropulse Visibility at ARVOhttps://modernod.com/news/iridex-announces-increase-in-micropulse-visibility-at-arvo/2480183/Iridex has announced that ARVO attendees will have access to over 20 posters presenting data on the use of MicroPulse technology. Eleven studies cover the use of MicroPulse technology for the treatment of glaucoma while the remaining studies present data on the use of MicroPulse for diverse patho
- Avedro Announces $25 Million in Funding to Fuel Innovation and Commercial Growthhttps://modernod.com/news/avedro-announces-25-million-in-funding-to-fuel-innovation-and-commercial-growth/2480188/Avedro announced that it has secured $25 million in financing to invest in product development, clinical studies and commercial efforts, including expansion of sales and reimbursement support. “Avedro’s mission is to develop noninvasive corneal remodeling treatments that protect and improv
- Aerie Announces US Launch of Rhopressahttps://modernod.com/news/aerie-announces-us-launch-of-rhopressa/2480197/Aerie Pharmaceuticals announced that it has launched Rhopressa in the United States. Rhopressa is now in national and regional US pharmaceutical distributors, and patients have access to Rhopressa through their local pharmacies across the nation. “We are pleased to announce the availabilit
- Johnson & Johnson Vision Highlights New Data at 2018 ARVO Annual Meetinghttps://modernod.com/news/johnson-johnson-vision-highlights-new-data-at-2018-arvo-annual-meeting/2480201/Johnson & Johnson Vision announced that a suite of new research from its eye health portfolio will be presented at the 2018 Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting in Honolulu, Hawaii from April 29 to M
- Allergan Presents Data at the ARVO Annual Meeting in Honoluluhttps://modernod.com/news/allergan-presents-data-at-the-arvo-annual-meeting-in-honolulu/2480202/Allergan announced that 19 posters on their eye care offerings will be presented at this year’s ARVO meeting in Hawaii. These presentations will cover a variety of topics in various subspecialties, including ocular surface, glaucoma, and retina. Retina Post
- EyePrint Prosthetics Announces Clinical Outcomes Achieved With EyePrintPROhttps://modernod.com/news/eyeprint-prosthetics-announces-clinical-outcomes-achieved-with-eyeprintpro/2480203/EyePrint Prosthetics, a company dedicated to restoring vision to patients who have complex corneal irregularities, announced the clinical outcomes that have been achieved since the EyePrintPRO lens was FDA-cleared 2 y
- MeiraGTx Announces AAV-RPGR Granted Fast Track Designation by FDA for Treatment of X-Linked Retinitis Pigmentosa Due to RPGR Deficiencyhttps://modernod.com/news/meiragtx-announces-aav-rpgr-granted-fast-track-designation-by-fda-for-treatment-of-x-linked-retinitis-pigmentosa-due-to-rpgr-deficiency/2480212/MeiraGTx Limited, a clinical stage gene therapy company, announced that the FDA has granted Fast Track designation for AAV-RPGR for the treatment of X-linked retinitis pigmentosa (XLRP) due to defects in the retinitis pigmentosa GTPase regulator (RPGR) gene. “XLRP is a devastating c
- CheckedUp Announces Content Licensing Initiative with The American Academy of Ophthalmology to Strengthen its Patient Education Offeringshttps://modernod.com/news/checkedup-announces-content-licensing-initiative-with-the-american-academy-of-ophthalmology-to-strengthen-its-patient-education-offerings/2480213/CheckedUp announced that it has singed a content licensing agreement with the American Academy of Ophthalmology (AAO) in which CheckedUp will provide professional programming produced by AAO on its waiting room and exam room technology platforms. “Our membership has continued its unprecede